Lead: Bryan Johnson, a high-profile biohacker, has drawn attention for treating penile function as a marker of biological age, using drugs and device therapies while tracking nocturnal erections. In 2024 Johnson, 48, said men who lack nighttime erections are “70% more likely to die prematurely,” a claim he uses to justify interventions such as low-dose Cialis, penile Botox and shockwave treatments. That message — part personal experiment, part health assertion — has prompted clinicians to explain what erectile changes actually tell us about cardiovascular and metabolic risk. This article summarizes expert views, evidence limits and practical guidance for men considering longevity-focused treatments for sexual function.
Key Takeaways
- Bryan Johnson (48) publicly tracks nocturnal erections and uses Cialis, penile Botox and low-intensity shockwave therapy as part of his longevity regimen.
- Johnson has said men without nighttime erections are 70% more likely to die prematurely; experts note this is an association, not proof of causation.
- Erectile dysfunction (ED) can precede cardiovascular events by roughly two to five years and is considered an early warning sign of vascular disease.
- Penile arteries are smaller than coronary arteries, so atherosclerotic changes may manifest earlier in erectile function than in the heart or brain.
- Common clinical tools include PDE5 inhibitors (Cialis/ sildenafil), brief-duration Botox injections (effects ~3–4 months), shockwave/acoustic therapies and platelet-rich plasma (P-shot); stem-cell and other injection therapies remain experimental and are not FDA-approved for ED.
- Consumer devices such as an Adam Health sensor (retail ~$249) are used by some to quantify nocturnal erections, but the clinical accuracy and prognostic value versus medical assessment are not fully established.
Background
Interest in using sexual function as a window into systemic health is not new: for decades clinicians have observed that erectile dysfunction often appears before recognized cardiovascular events. The so-called “artery size” explanation posits that because penile arteries are narrower than coronary arteries, small changes in vascular health can impair erections earlier than they impair cardiac blood flow. That physiological relationship has encouraged both clinicians and longevity enthusiasts to monitor erectile markers as an early alarm for metabolic and vascular disease.
In recent years a subculture of biohackers and fitness influencers has amplified these ideas, combining constant biomarker tracking with off-label or experimental treatments aimed at restoring youthful sexual performance. High-profile figures such as Bryan Johnson and Ben Greenfield have publicized device use and injections to optimize penile blood flow and sensation. That activity sits at the intersection of consumer health technology, aesthetic and regenerative clinics, and regulators — producing demand for interventions whose long-term safety and effectiveness vary greatly.
Main Event
Johnson’s regimen, as he describes it publicly, pairs lifestyle optimization with targeted interventions: daily low-dose tadalafil (Cialis) to relax smooth muscle, Botox injections to alter local nerve signaling, and sessions of low-intensity focused shockwave therapy to stimulate local vascular repair. He also tracks nocturnal erection frequency and duration with a consumer device costing about $249 and records semen parameters, penile blood flow measures and prostate size. These practices are intended both to improve sexual function and to serve as proxies for biological age.
Clinicians interviewed by the Post — including Dr. Ryan Welter and aesthetic practitioner Chris Bustamante — acknowledged that erectile changes convey meaningful health information but urged caution. Dr. Welter emphasized ED’s role as an early marker of cardiovascular disease, while Bustamante described the mechanics and immediate effects of interventions such as shockwave therapy, Botox and platelet-rich plasma (P-shot). Both stressed that metabolic health, diet and exercise remain the primary, evidence-based foundations for longevity and penile health.
Procedures differ in evidence and regulatory status. Low-dose PDE5 inhibitors have a long safety track and are prescribed for ED and lower urinary tract symptoms. Botox injections into penile tissue can alter local contractility for months but are typically used for symptomatic improvement rather than proven longevity benefits. Shockwave and acoustic therapies aim to provoke microrepair and new vessel growth; proponents report functional gains in some patients, but protocols, device energy levels and long-term outcomes vary across clinics. Stem-cell injections and other experimental injectables are promoted in some private clinics despite lacking robust safety and efficacy data and without FDA approval for treating ED.
Analysis & Implications
Using erections as a biomarker has strengths and limits. Strengths include objective features (frequency, rigidity, nocturnal occurrence) that correlate with vascular health and can prompt cardiovascular evaluation earlier than symptom-based detection alone. However, erectile function is multifactorial: neurologic health, hormonal status, mental health, medications, lifestyle and local penile pathology all influence outcomes. Thus, a change in erections should trigger a structured medical assessment rather than automatic escalation to unproven therapies.
The biohacking approach — continuous self-tracking combined with targeted interventions — can accelerate detection of problems but risks over-interpretation of noisy signals. Consumer sensors and short-term functional gains after an intervention may create a false sense of disease prevention. For example, short-lived improvements in erection firmness do not equate to reduced long-term cardiovascular risk unless underlying metabolic and vascular risk factors are addressed.
There are also safety and equity implications. Many regenerative or aesthetic procedures are costly and delivered outside conventional trial frameworks; some clinics offer stem-cell or off-label injections that lack standardized manufacturing and safety oversight. Widespread uptake of such practices could expose men to infection, immune reactions, or unanticipated long-term harms, while diverting attention and resources from proven cardiovascular prevention strategies like lipid management, blood pressure control and exercise.
Comparison & Data
| Intervention | Typical Evidence/Status | Expected Duration of Effect |
|---|---|---|
| PDE5 inhibitors (Cialis, sildenafil) | Strong clinical evidence for symptomatic ED; widely prescribed | Hours–ongoing with chronic dosing |
| Penile Botox | Small clinical series for symptomatic use; off-label for ED | ~3–4 months |
| Low‑intensity shockwave/acoustic therapy | Mixed evidence; some trials report improved function, protocols vary | Variable; months |
| P‑shot (PRP) | Limited controlled data; biologically plausible but not definitive | Months; patient-reported |
| Penile stem-cell injections | Experimental; not FDA-approved for ED; safety/efficacy unproven | Unknown |
The table above summarizes the current practical landscape: established pharmaceuticals lead in predictable efficacy, while device-based and biologic procedures occupy a spectrum from promising to experimental. That distinction matters for clinicians deciding whether to recommend an approach to men seeking longevity-focused sexual optimization.
Reactions & Quotes
Experts say monitoring erections can be clinically valuable but must be interpreted within a broader risk assessment.
“Erectile dysfunction often shows up two to five years before a heart attack,”
Dr. Ryan Welter (regenerative clinician), summarizing vascular links to ED
Practitioners who offer regenerative and aesthetic procedures explain the intended local effects and limitations.
“Shockwave devices create micro-injuries that can encourage new vessel growth, but energy levels and depth vary and influence outcomes,”
Chris Bustamante (aesthetic nurse practitioner)
Unconfirmed
- The precise causal interpretation of Johnson’s claim that absence of nighttime erections increases premature mortality risk by 70% has not been established; existing data support association but not direct proof that treating erections reduces mortality.
- Long-term safety and effectiveness of penile stem-cell injections, salmon-sperm derivatives and many proprietary injectables remain unproven and lack rigorous trial data.
- The prognostic accuracy of consumer nocturnal-erection sensors compared with formal clinical testing and cardiovascular risk stratification has not been fully validated.
Bottom Line
Erectile function provides useful clinical signals about vascular and metabolic health and can motivate appropriate cardiovascular assessment. However, it is one piece of a larger clinical picture: lifestyle, metabolic control and established cardiovascular prevention remain the primary levers to extend healthy lifespan.
For men curious about biohacking sexual function in the name of longevity, the prudent path is structured medical evaluation first, evidence-based therapy second, and cautious consideration of experimental procedures only within well-designed clinical studies or with clear informed-consent discussion of uncertain benefit and potential risk.